ESC 365 - Verinurad plus allopurinol for heart failure with preserved ejection fraction: results from the AMETHYST randomized controlled trial

HFA Premium Access

Verinurad plus allopurinol for heart failure with preserved ejection fraction: results from the AMETHYST randomized controlled trial

Session: Late breaking clinical trials: medical therapy

Topic: Pharmacotherapy

Speaker: Professor A. Voors (Groningen, NL)

Event: Heart Failure 2023

Congress Presentation

Add to my library

About the speaker

Professor Adriaan Voors

University Medical Centre Groningen, Groningen (Netherlands (The))

77 presentations

1 follower

4 more presentations in this session

PARAGLIDEHF: Sacubitril/Valsartan versus valsartan on changes in NTproBNP, safety, and tolerability in patients with EF>40% stabilized after a WHF Event

Speaker: Doctor R. Mentz (Durham, US)

A pre-specified, participant-level pooled analysis of PARAGON-HF and PARAGLIDE-HF

Speaker: Doctor M. Vaduganathan (Boston, US)

STEP HFpEF trial design and baseline characteristics

Speaker: Doctor M. Kosiborod (Kansas City, US)

DAPA-RESIST clinical trial - Dapagliflozin versus metolazone in heart failure with diuretic resistance

Speaker: Doctor R. Campbell (Glasgow, GB)

Access the full session

Late breaking clinical trials: medical therapy

Speakers: Professor A. Voors, Doctor R. Mentz, Doctor M. Vaduganathan, Doctor M. Kosiborod, Doctor R. Campbell

About the event

Heart Failure 2023

20 May - 23 May 2023

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources